HMGA and Cancer: A Review on Patent Literatures

Author(s): Marco De Martino, Alfredo Fusco, Francesco Esposito*.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 14 , Issue 3 , 2019

Become EABM
Become Reviewer

Abstract:

Background: The high mobility group A proteins modulate the transcription of numerous genes by interacting with transcription factors and/or altering the structure of chromatin. These proteins are involved in both benign and malignant neoplasias as a result of several pathways. A large amount of benign human mesenchymal tumors has rearrangements of HMGA genes. On the contrary, malignant tumors show unarranged HMGA overexpression that is frequently and causally related to neoplastic cell transformation. Here, we review the function of the HMGA proteins in human neoplastic disorders, the pathways by which they contribute to carcinogenesis and the new patents focused on targeting HMGA proteins.

Objective: Current review was conducted to check the involvement of HMGA as a druggable target in cancer treatment.

Methods: We reviewed the most recent patents focused on targeting HMGA in cancer treatment analyzing patent literature published during the last years, including the World Intellectual Property Organization (WIPO®), United States Patent Trademark Office (USPTO®), Espacenet®, and Google Patents.

Results: HMGA proteins are intriguing targets for cancer therapy and are objects of different patents based on the use of DNA aptamers, inhibitors, oncolytic viruses, antisense molecules able to block their oncogenic functions.

Conclusion: Powerful strategies able to selectively interfere with HMGA expression and function could represent a helpful approach in the development of new anti-cancer therapies.

Keywords: Anti-cancer therapies, antisense RNA, cancer, cancer stem cells, HMGA, HMGA1, HMGA1 inhibitors, HMGA2.

[1]
Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001; 26(3): 152-3.
[http://dx.doi.org/10.1016/S0968-0004(00)01777-1] [PMID: 11246012]
[2]
Catez F, Hock R. Binding and interplay of HMG proteins on chromatin: Lessons from live cell imaging. Biochim Biophys Acta 2010; 1799(1-2): 15-27.
[http://dx.doi.org/10.1016/j.bbagrm.2009.11.001] [PMID: 20123065]
[3]
Reeves R. Molecular biology of HMGA proteins: Hubs of nuclear function. Gene 2001; 277(1-2): 63-81.
[http://dx.doi.org/10.1016/S0378-1119(01)00689-8] [PMID: 11602345]
[4]
Reeves R. Nuclear functions of the HMG proteins. Biochim Biophys Acta 2010; 1799(1-2): 3-14.
[http://dx.doi.org/10.1016/j.bbagrm.2009.09.001] [PMID: 19748605]
[5]
Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem 1988; 263(34): 18338-42.
[PMID: 3192537]
[6]
Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 1993; 21(18): 4259-67.
[http://dx.doi.org/10.1093/nar/21.18.4259] [PMID: 8414980]
[7]
Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992; 71(5): 777-89.
[http://dx.doi.org/10.1016/0092-8674(92)90554-P] [PMID: 1330326]
[8]
Du W, Maniatis T. The high mobility group protein HMG I(Y) can stimulate or inhibit DNA binding of distinct transcription factor ATF-2 isoforms. Proc Natl Acad Sci USA 1994; 91(24): 11318-22.
[http://dx.doi.org/10.1073/pnas.91.24.11318] [PMID: 7972056]
[9]
Falvo JV, Thanos D, Maniatis T. Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 1995; 83(7): 1101-11.
[http://dx.doi.org/10.1016/0092-8674(95)90137-X] [PMID: 8548798]
[10]
Thanos D, Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 1995; 83(7): 1091-100.
[http://dx.doi.org/10.1016/0092-8674(95)90136-1] [PMID: 8548797]
[11]
Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell 2007; 129(6): 1111-23.
[http://dx.doi.org/10.1016/j.cell.2007.05.019] [PMID: 17574024]
[12]
Apostolou E, Thanos D. Virus Infection Induces NF-kappaB-dependent interchromosomal associations mediating monoallelic IFN-beta gene expression. Cell 2008; 134(1): 85-96.
[http://dx.doi.org/10.1016/j.cell.2008.05.052] [PMID: 18614013]
[13]
Ford E, Thanos D. The transcriptional code of human IFN-beta gene expression. Biochim Biophys Acta 2010; 1799(3-4): 328-36.
[http://dx.doi.org/10.1016/j.bbagrm.2010.01.010] [PMID: 20116463]
[14]
Cui T, Leng F. Specific recognition of AT-rich DNA sequences by the mammalian high mobility group protein AT-hook 2: A SELEX study. Biochemistry 2007; 46(45): 13059-66.
[http://dx.doi.org/10.1021/bi701269s] [PMID: 17956125]
[15]
Winter N, Nimzyk R, Bösche C, Meyer A, Bullerdiek J. Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2. PLoS One 2011; 6(4) e18837
[http://dx.doi.org/10.1371/journal.pone.0018837] [PMID: 21533145]
[16]
Li O, Vasudevan D, Davey CA, Dröge P. High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis 2006; 44(11): 523-9.
[http://dx.doi.org/10.1002/dvg.20242] [PMID: 17078040]
[17]
Xu M, Sharma P, Pan S, Malik S, Roeder RG, Martinez E. Core promoter-selective function of HMGA1 and mediator in initiator-dependent transcription. Genes Dev 2011; 25(23): 2513-24.
[http://dx.doi.org/10.1101/gad.177360.111] [PMID: 22156211]
[18]
Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7(12): 899-910.
[http://dx.doi.org/10.1038/nrc2271] [PMID: 18004397]
[19]
Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007; 17(2): 72-9.
[http://dx.doi.org/10.1016/j.tcb.2006.12.001] [PMID: 17169561]
[20]
Giancotti V, Berlingieri MT, DiFiore PP, Fusco A, Vecchio G, Crane-Robinson C. Changes in nuclear proteins on transformation of rat epithelial thyroid cells by a murine sarcoma retrovirus. Cancer Res 1985; 45(12 Pt 1): 6051-7.
[PMID: 2998592]
[21]
Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000; 60(15): 4256-61.
[PMID: 10945639]
[22]
Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001; 21(2): 575-94.
[http://dx.doi.org/10.1128/MCB.21.2.575-594.2001] [PMID: 11134344]
[23]
Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, et al. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 2008; 6(5): 743-50.
[http://dx.doi.org/10.1158/1541-7786.MCR-07-0095] [PMID: 18505920]
[24]
Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011; 473(7345): 101-4.
[http://dx.doi.org/10.1038/nature09881] [PMID: 21471965]
[25]
Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, et al. HMGA2 is a driver of tumor metastasis. Cancer Res 2013; 73(14): 4289-99.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-3848] [PMID: 23722545]
[26]
Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA 2013; 110(24): 9920-5.
[http://dx.doi.org/10.1073/pnas.1305172110] [PMID: 23716660]
[27]
Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006; 9(6): 459-71.
[http://dx.doi.org/10.1016/j.ccr.2006.04.024] [PMID: 16766265]
[28]
Massimi I, Guerrieri F, Petroni M, Veschi V, Truffa S, Screpanti I, et al. The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1. Mol Carcinog 2013; 52(7): 526-34.
[http://dx.doi.org/10.1002/mc.21887] [PMID: 22389255]
[29]
Casalino L, Bakiri L, Talotta F, Weitzman JB, Fusco A, Yaniv M, et al. FRA-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J 2007; 26(7): 1878-90.
[http://dx.doi.org/10.1038/sj.emboj.7601617] [PMID: 17347653]
[30]
Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, et al. Neoplastic transformation of rat thyroid cells requires the JUNB and FRA-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 1997; 16(17): 5310-21.
[http://dx.doi.org/10.1093/emboj/16.17.5310] [PMID: 9311991]
[31]
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7(2): 131-42.
[http://dx.doi.org/10.1038/nrm1835] [PMID: 16493418]
[32]
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6): 1420-8.
[http://dx.doi.org/10.1172/JCI39104] [PMID: 19487818]
[33]
Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21(9): 1025-30.
[http://dx.doi.org/10.1101/gad.1540407] [PMID: 17437991]
[34]
Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 2006; 174(2): 175-83.
[http://dx.doi.org/10.1083/jcb.200512110] [PMID: 16831886]
[35]
Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 2008; 283(48): 33437-46.
[http://dx.doi.org/10.1074/jbc.M802016200] [PMID: 18832382]
[36]
Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009; 174(3): 854-68.
[http://dx.doi.org/10.2353/ajpath.2009.080523] [PMID: 19179606]
[37]
Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 2011; 71(2): 349-59.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-2550] [PMID: 21224353]
[38]
Zha L, Wang Z, Tang W, Zhang N, Liao G, Huang Z. Genome-wide analysis of HMGA2 transcription factor binding sites by ChIP on chip in gastric carcinoma cells. Mol Cell Biochem 2012; 364(1-2): 243-51.
[http://dx.doi.org/10.1007/s11010-012-1224-z] [PMID: 22246783]
[39]
Golestaneh N, Mishra B. TGF-beta, neuronal stem cells and glioblastoma. Oncogene 2005; 24(37): 5722-30.
[http://dx.doi.org/10.1038/sj.onc.1208925] [PMID: 16123805]
[40]
Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009; 5(5): 504-14.
[http://dx.doi.org/10.1016/j.stem.2009.08.018] [PMID: 19896441]
[41]
Thornton JE, Gregory RI. How does Lin28 let-7 control development and disease? Trends Cell Biol 2012; 22(9): 474-82.
[http://dx.doi.org/10.1016/j.tcb.2012.06.001] [PMID: 22784697]
[42]
Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q, Ramanujan K, et al. An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis. Dev Cell 2012; 23(6): 1176-88.
[http://dx.doi.org/10.1016/j.devcel.2012.10.019] [PMID: 23177649]
[43]
Copley MR, Babovic S, Benz C, Knapp DJ, Beer PA, Kent DG, et al. The Lin28b-let-7-HMGA2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nat Cell Biol 2013; 15(8): 916-25.
[http://dx.doi.org/10.1038/ncb2783] [PMID: 23811688]
[44]
Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007; 104(27): 11400-5.
[http://dx.doi.org/10.1073/pnas.0704372104] [PMID: 17600087]
[45]
Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011; 147(1): 81-94.
[http://dx.doi.org/10.1016/j.cell.2011.08.033] [PMID: 21962509]
[46]
Wu J, Wei JJ. HMGA2 and high-grade serous ovarian carcinoma. J Mol Med (Berl) 2013; 91(10): 1155-65.
[http://dx.doi.org/10.1007/s00109-013-1055-8] [PMID: 23686260]
[47]
Shah SN, Kerr C, Cope L, Zambidis E, Liu C, Hillion J, et al. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One 2012; 7(11) e48533
[http://dx.doi.org/10.1371/journal.pone.0048533] [PMID: 23166588]
[48]
Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998; 58(18): 4193-8.
[PMID: 9751634]
[49]
Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, et al. The expression of the high mobility group HMGI(Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995; 10(7): 1307-14.
[PMID: 7731681]
[50]
Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, et al. Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid. Genes Chromosomes Cancer 1999; 24(3): 286-9.
[http://dx.doi.org/10.1002/(SICI)1098-2264(199903)24:3<286:AID-GCC16>3.0.CO;2-E] [PMID: 10451711]
[51]
Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006; 209(2): 206-12.
[http://dx.doi.org/10.1002/path.1960] [PMID: 16521118]
[52]
Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, Kowalski J, et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res 2009; 7(11): 1803-12.
[http://dx.doi.org/10.1158/1541-7786.MCR-08-0336] [PMID: 19903768]
[53]
Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, et al. Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004; 149(2): 98-106.
[http://dx.doi.org/10.1016/S0165-4608(03)00300-5] [PMID: 15036884]
[54]
Shah SN, Cope L, Poh W, Belton A, Roy S, Talbot CC Jr, et al. HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells. PLoS One 2013; 8(5) e63419
[http://dx.doi.org/10.1371/journal.pone.0063419] [PMID: 23658826]
[55]
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40(5): 499-507.
[http://dx.doi.org/10.1038/ng.127] [PMID: 18443585]
[56]
Dolde CE, Mukherjee M, Cho C, Resar LM. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002; 71(3): 181-91.
[http://dx.doi.org/10.1023/A:1014444114804] [PMID: 12002338]
[57]
Holth LT, Thorlacius AE, Reeves R. Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in human mammary epithelial cell lines. DNA Cell Biol 1997; 16(11): 1299-309.
[http://dx.doi.org/10.1089/dna.1997.16.1299] [PMID: 9407002]
[58]
Flohr AM, Rogalla P, Bonk U, Puettmann B, Buerger H, Gohla G, et al. High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 2003; 18(4): 999-1004.
[PMID: 12973668]
[59]
Takaha N, Resar LM, Vindivich D, Coffey DS. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 2004; 60(2): 160-7.
[http://dx.doi.org/10.1002/pros.20049] [PMID: 15162382]
[60]
Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. High mobility group protein I(Y): A candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res 2002; 62(3): 647-51.
[PMID: 11830513]
[61]
Belton A, Gabrovsky A, Bae YK, Reeves R, Iacobuzio-Donahue C, Huso DL, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 2012; 7(1) e30034
[http://dx.doi.org/10.1371/journal.pone.0030034] [PMID: 22276142]
[62]
Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 1996; 56(8): 1896-901.
[PMID: 8620511]
[63]
Chiappetta G, Manfioletti G, Pentimalli F, Abe N, Di Bonito M, Vento MT, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 2001; 91(2): 147-51.
[http://dx.doi.org/10.1002/1097-0215(200002)9999:9999<:AID-IJC1033>3.3.CO;2-M] [PMID: 11146437]
[64]
Cleynen I, Huysmans C, Sasazuki T, Shirasawa S, Van de Ven W, Peeters K. Transcriptional control of the human high mobility group A1 gene: Basal and oncogenic RAS-regulated expression. Cancer Res 2007; 67(10): 4620-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-4325] [PMID: 17510387]
[65]
Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, Hillion JA, et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 2010; 23(1): 98-104.
[http://dx.doi.org/10.1038/modpathol.2009.139] [PMID: 19820691]
[66]
Abe N, Watanabe T, Masaki T, Mori T, Sugiyama M, Uchimura H, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 2000; 60(12): 3117-22.
[PMID: 10866296]
[67]
Liau SS, Jazag A, Ito K, Whang EE. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Br J Cancer 2007; 96(6): 993-1000.
[http://dx.doi.org/10.1038/sj.bjc.6603654] [PMID: 17342093]
[68]
Tesfaye A, Di Cello F, Hillion J, Ronnett BM, Elbahloul O, Ashfaq R, et al. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 2007; 67(9): 3998-4004.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-1684] [PMID: 17483309]
[69]
Bandiera A, Bonifacio D, Manfioletti G, Mantovani F, Rustighi A, Zanconati F, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998; 58(3): 426-31.
[PMID: 9458084]
[70]
Takaha N, Sowa Y, Takeuchi I, Hongo F, Kawauchi A, Miki T. Expression and role of HMGA1 in renal cell carcinoma. J Urol 2012; 187(6): 2215-22.
[http://dx.doi.org/10.1016/j.juro.2012.01.069] [PMID: 22503056]
[71]
Rho YS, Lim YC, Park IS, Kim JH, Ahn HY, Cho SJ, et al. High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol 2007; 127(1): 76-81.
[http://dx.doi.org/10.1080/00016480600740571] [PMID: 17364334]
[72]
Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, et al. Molecular mechanism of HMGA1 deregulation in human neuroblastoma. Cancer Lett 2005; 228(1-2): 97-104.
[http://dx.doi.org/10.1016/j.canlet.2005.01.045] [PMID: 15923078]
[73]
Cerignoli F, Ambrosi C, Mellone M, Assimi I, di Marcotullio L, Gulino A, et al. HMGA molecules in neuroblastic tumors. Ann N Y Acad Sci 2004; 1028: 122-32.
[http://dx.doi.org/10.1196/annals.1322.013] [PMID: 15650238]
[74]
Giannini G, Kim CJ, Di Marcotullio L, Manfioletti G, Cardinali B, Cerignoli F, et al. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br J Cancer 2000; 83(11): 1503-9.
[http://dx.doi.org/10.1054/bjoc.2000.1494] [PMID: 11076660]
[75]
Rahman MM, Qian ZR, Wang EL, Sultana R, Kudo E, Nakasono M, et al. Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer 2009; 100(3): 501-10.
[http://dx.doi.org/10.1038/sj.bjc.6604883] [PMID: 19156147]
[76]
Chieffi P, De Martino M, Esposito F. New anti-cancer strategies in testicular germ cell tumors. Recent Patents Anticancer Drug Discov 2019; 14(1): 53-9.
[http://dx.doi.org/10.2174/1574892814666190111120023] [PMID: 30636617]
[77]
Esposito F, Boscia F, Gigantino V, Tornincasa M, Fusco A, Franco R, et al. The high-mobility group A1-estrogen receptor β nuclear interaction is impaired in human testicular seminomas. J Cell Physiol 2012; 227(12): 3749-55.
[http://dx.doi.org/10.1002/jcp.24087] [PMID: 22392906]
[78]
Franco R, Esposito F, Fedele M, Liguori G, Pierantoni GM, Botti G, et al. Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours. J Pathol 2008; 214(1): 58-64.
[http://dx.doi.org/10.1002/path.2249] [PMID: 17935122]
[79]
Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: An achilles heel for hematopoietic malignancies? Cancer Res 2008; 68(24): 10121-7.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2121] [PMID: 19074878]
[80]
Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, et al. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000; 20(15): 5490-502.
[http://dx.doi.org/10.1128/MCB.20.15.5490-5502.2000] [PMID: 10891489]
[81]
Pierantoni GM, Agosti V, Fedele M, Bond H, Caliendo I, Chiappetta G, et al. High-mobility group A1 proteins are overexpressed in human leukaemias. Biochem J 2003; 372(Pt 1): 145-50.
[http://dx.doi.org/10.1042/bj20021493] [PMID: 12573034]
[82]
Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011; 117(12): 3302-10.
[http://dx.doi.org/10.1182/blood-2010-09-310862] [PMID: 21239698]
[83]
Nelson DM, Joseph B, Hillion J, Segal J, Karp JE, Resar LM. Flavopiridol induces Bcl-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 2011; 52(10): 1999-2006.
[http://dx.doi.org/10.3109/10428194.2011.591012] [PMID: 21728742]
[84]
Chuma M, Saeki N, Yamamoto Y, Ohta T, Asaka M, Hirohashi S, et al. Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: Identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J Med 2004; 53(2): 90-7.
[http://dx.doi.org/10.2302/kjm.53.90] [PMID: 15247513]
[85]
Roy S, Di Cello F, Kowalski J, Hristov AC, Tsai HL, Bhojwani D, et al. HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leuk Lymphoma 2013; 54(11): 2565-7.
[http://dx.doi.org/10.3109/10428194.2013.782610] [PMID: 23472968]
[86]
D’Angelo D, Mussnich P, Rosa R, Bianco R, Tortora G, Fusco A. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer 2014; 14: 851.
[http://dx.doi.org/10.1186/1471-2407-14-851] [PMID: 25409711]
[87]
Hassan F, Lossie SL, Kasik EP, Channon AM, Ni S, Kennedy MA. A mouse model study of toxicity and biodistribution of a replication defective adenovirus serotype 5 virus with its genome engineered to contain a decoy hyper binding site to sequester and suppress oncogenic HMGA1 as a new cancer treatment therapy. PLoS One 2018; 13(2) e0192882
[http://dx.doi.org/10.1371/journal.pone.0192882] [PMID: 29462157]
[88]
Esposito F, De Martino M, Petti MG, Forzati F, Tornincasa M, Federico A, et al. HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. Oncotarget 2014; 5(18): 8341-54.
[http://dx.doi.org/10.18632/oncotarget.2202] [PMID: 25268743]
[89]
Esposito F, De Martino M, Forzati F, Fusco A. HMGA1-pseudogene overexpression contributes to cancer progression. Cell Cycle 2014; 13(23): 3636-9.
[http://dx.doi.org/10.4161/15384101.2014.974440] [PMID: 25483074]
[90]
Esposito F, De Martino M, D’Angelo D, Mussnich P, Raverot G, Jaffrain-Rea ML, et al. HMGA1-pseudogene expression is induced in human pituitary tumors. Cell Cycle 2015; 14(9): 1471-5.
[http://dx.doi.org/10.1080/15384101.2015.1021520] [PMID: 25894544]
[91]
De Martino M, Palma G, Azzariti A, Arra C, Fusco A, Esposito F. The HMGA1 pseudogene 7 induces miR-483 and miR-675 upregulation by activating EGR1 through a ceRNA mechanism. Genes (Basel) 2017; 8(11): 8.
[http://dx.doi.org/10.3390/genes8110330] [PMID: 29149041]
[92]
De Martino M, Forzati F, Marfella M, Pellecchia S, Arra C, Terracciano L, et al. HMGA1P7-pseudogene regulates H19 and IGF2 expression by a competitive endogenous RNA mechanism. Sci Rep 2016; 6: 37622.
[http://dx.doi.org/10.1038/srep37622] [PMID: 27874091]
[93]
De Martino M, Forzati F, Arra C, Fusco A, Esposito F. HMGA1-pseudogenes and cancer. Oncotarget 2016; 7(19): 28724-35.
[http://dx.doi.org/10.18632/oncotarget.7427] [PMID: 26895108]
[94]
D’Angelo D, Esposito F, Fusco A. Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas. Front Med (Lausanne) 2015; 2: 39.
[PMID: 26137461]
[95]
Palmieri D, Valentino T, De Martino I, Esposito F, Cappabianca P, Wierinckx A, et al. PIT1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocr Relat Cancer 2012; 19(2): 123-35.
[http://dx.doi.org/10.1530/ERC-11-0135] [PMID: 22199144]
[96]
Watanabe M, Sheriff S, Lewis KB, Tinch SL, Cho J, Balasubramaniam A, et al. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines. Cancer Lett 2012; 315(1): 18-27.
[http://dx.doi.org/10.1016/j.canlet.2011.10.005] [PMID: 22036895]
[97]
Kennedy MA. Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells. US9233119 . (2016).
[98]
Resar LM, Huso D, Cope L. Methods of inhibiting cancer stem cells with HMGA1 inhibitors. US9545417 . (2015).
[99]
Kennedy MA. Engineered oncolytic viruses containing hyperbinding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer. US20180099014 . (2018).
[100]
Bonci D, De Maria R. Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration. US9261508. (2016).
[101]
Fusco A, Orlandi A, Nolli ML. Anti-HMGA1 monoclonal antibodies, process for their preparation and their use for the quantitative determination of HMGA1. US20050152903 . (2013).
[102]
Capo A, Sepe R, Pellino G, Milone M, Malapelle U, Pellecchia S, et al. Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. Nanomedicine (Lond) 2019; 15(1): 231-42.
[http://dx.doi.org/10.1016/j.nano.2018.09.011] [PMID: 30308301]
[103]
Kaishan Z. In vitro diagnostic kit for detecting HMGA2 (High Mobility Group A) content with enzyme-linked immuno sorbent assay. CN102375064. (2010).


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 3
Year: 2019
Page: [258 - 267]
Pages: 10
DOI: 10.2174/1574892814666190919152001

Article Metrics

PDF: 27
HTML: 4

Special-new-year-discount